Study ID: NCI CO10904
Description:
A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer
Location:
Sioux Falls Region
Principal Investigator:
Maria Bell MD
Disease:
Stage:
Phase I
Status:
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.
Back to Clinical Trials list